Although it is unclear whether LRP6 is up-regulated in prostate cancer, we have recently demonstrated that the LRP6 antagonist Mesd markedly inhibited Wnt/β-catenin signaling in prostate cancer PC-3 cells, and suppressed PC-3 cell proliferation in vitro and tumor growth in vivo[42], [43]. Here, LRP6 is linked to prostate carcinoma.